Sanctuary Advisors LLC Trims Position in Genmab A/S Sponsored ADR $GMAB

Sanctuary Advisors LLC decreased its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 84.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,850 shares of the company’s stock after selling 57,908 shares during the quarter. Sanctuary Advisors LLC’s holdings in Genmab A/S were worth $291,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Orbis Allan Gray Ltd boosted its position in Genmab A/S by 30.2% in the 4th quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock valued at $444,089,000 after buying an additional 3,340,456 shares during the period. Paradigm Biocapital Advisors LP increased its position in shares of Genmab A/S by 84.4% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,039,834 shares of the company’s stock worth $216,827,000 after acquiring an additional 3,222,983 shares during the period. Arrowstreet Capital Limited Partnership increased its position in shares of Genmab A/S by 36.6% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock worth $153,324,000 after acquiring an additional 1,334,919 shares during the period. Renaissance Technologies LLC raised its stake in shares of Genmab A/S by 23.8% during the fourth quarter. Renaissance Technologies LLC now owns 3,492,850 shares of the company’s stock valued at $107,580,000 after acquiring an additional 671,307 shares in the last quarter. Finally, Morgan Stanley raised its stake in shares of Genmab A/S by 9.5% during the fourth quarter. Morgan Stanley now owns 1,834,439 shares of the company’s stock valued at $56,501,000 after acquiring an additional 159,865 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on GMAB shares. BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. TD Cowen raised Genmab A/S from a “hold” rating to a “buy” rating and lifted their target price for the company from $32.00 to $43.00 in a research report on Wednesday, July 22nd. HC Wainwright upped their target price on Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. Finally, Truist Financial started coverage on Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus target price of $39.28.

Genmab A/S Trading Up 0.8%

NASDAQ:GMAB opened at $28.87 on Friday. The firm has a 50-day simple moving average of $27.03 and a 200-day simple moving average of $28.16. Genmab A/S Sponsored ADR has a one year low of $21.00 and a one year high of $35.43. The firm has a market cap of $18.00 billion, a P/E ratio of 21.87, a P/E/G ratio of 1.80 and a beta of 0.84. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18.

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.